Bofanglutide

2 papers5 findings

Outcomes

Body weight

downin humans2−9.3%

2 studies

Bofanglutide decreases body weight in humans.
“GZR18 also surpassed SEMA in most secondary efficacy measures, including body weight.”
Human trialtype 2 diabetes24 weeks
Efficacy and Safety of Bofanglutide (GZR18), a Biweekly GLP-1RA, Compared with Semaglutide in Chinese Patients with T2D
ADA Scientific Sessions 2025 abstractJun 13, 2025
Bofanglutide decreases body weight in humans (-9.25 %).
“significant reductions in body weight (-9.25 %)”
Human trialT2D1.5 mg to 13 mg23 weeks
Bofanglutide (GZR18), a Novel GLP-1RA, Improved Glycemic Control and Cardiometabolic Risk Factors in Chinese Patients with T2D
ADA Scientific Sessions 2025 abstractJun 13, 2025

HbA1c

downin humans2

2 studies

Bofanglutide decreases HbA1c in humans (-1.87% to -2.32% vs -1.6%).
“The LSM HbA1c reductions were greater in GZR18 groups (-1.87% to -2.32%) than in the SEMA group (-1.6%)”
Human trialtype 2 diabetes24 weeks
Efficacy and Safety of Bofanglutide (GZR18), a Biweekly GLP-1RA, Compared with Semaglutide in Chinese Patients with T2D
ADA Scientific Sessions 2025 abstractJun 13, 2025
Bofanglutide decreases HbA1c in humans (-1.81 % vs 0.12 %).
“By week 23, the GZR18 group exhibited a greater reduction in HbA1c of -1.81 % compared to 0.12 % in the placebo group”
Human trialT2D1.5 mg to 13 mg23 weeks
Bofanglutide (GZR18), a Novel GLP-1RA, Improved Glycemic Control and Cardiometabolic Risk Factors in Chinese Patients with T2D
ADA Scientific Sessions 2025 abstractJun 13, 2025